Publicação

Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey

Ver documento

Detalhes bibliográficos
Resumo:Abstract Introduction: Patients with inflammatory bowel disease (IBD) do not seem to be at increased risk of infection by SARS-CoV-2, but there is a concern whether immunosuppressive therapy may be associated with more severe disease. Several clinical practice recommendations have been published to help guide IBD care during the COVID-19 pandemic. Nonetheless, few studies have addressed patients’ perspectives and fears. We aimed to evaluate Portuguese IBD patients’ perspectives on the clinical management of their disease during the SARS-CoV-2 pandemic as well as the impact on their professional life. Methods: An anonymous electronic survey was created using REDCap and was distributed by the Portuguese Association of Inflammatory Bowel Disease (APDI) between May and August 2020. Patients’ perspectives on immunosuppressive therapy, disease management, interaction with gastroenterology departments, and the impact of the pandemic in their professional life were assessed. Patients’ proposals to improve medical care were also evaluated. Descriptive analysis and logistic regression were performed. Results: A total of 137 participants answered the survey (79.6% females, mean age 41.7 ± 12.1 years). Although having IBD and receiving treatment with immunosuppressors (thiopurines, steroids, or biologics) were considered promotors of anxiety, most patients (85.4%) agreed that disease remission was a priority and only a minority of patients interrupted their treatment during the pandemic. In multivariate analysis, active disease, biologic treatment, and use of corticosteroids in the last 3 months were perceived by the patients as high-risk features for increased risk of SARS-Cov-2 infection and more severe disease. Fifty-nine patients (44%) believed that their follow-up was influenced by the pandemic and only 58.8% felt that they had the opportunity to discuss their therapeutic options with their doctor. Sixty-three patients (46.0%) were working from home during the pandemic, although this decision was related to IBD and immunosuppressive therapy in only 36.5 and 39.7% of the cases, respectively. Areas where care could have been improved during the pandemic were identified by patients, namely enhancement of the communication with IBD professionals, conciliation of telemedicine with face-to-face appointments, and facilitation of the interaction between patients and employers. Conclusion: Most patients agreed that maintaining IBD remission is crucial, and only a minority of the patients stopped their treatment as per their own initiative. IBD status only had a small influence on patients’ professional activity during the COVID-19 outbreak, with most changes being related to the pandemic itself.
Autores principais:Revés,Joana Branco
Outros Autores:Frias-Gomes,Catarina; Morão,Bárbara; Nascimento,Catarina; Palmela,Carolina; Fidalgo,Catarina; Ramos,Lídia Roque; Sampaio,Ana; Glória,Luísa; Cravo,Marília; Torres,Joana
Assunto:Inflammatory bowel disease Crohn’s disease Ulcerative colitis COVID-19
Ano:2022
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Fundação para a Ciência e Tecnologia
Idioma:inglês
Origem:SciELO Portugal
_version_ 1868441988398841856
author Revés,Joana Branco
author2 Frias-Gomes,Catarina
Morão,Bárbara
Nascimento,Catarina
Palmela,Carolina
Fidalgo,Catarina
Ramos,Lídia Roque
Sampaio,Ana
Glória,Luísa
Cravo,Marília
Torres,Joana
author2_role author
author
author
author
author
author
author
author
author
author
author_facet Revés,Joana Branco
Frias-Gomes,Catarina
Morão,Bárbara
Nascimento,Catarina
Palmela,Carolina
Fidalgo,Catarina
Ramos,Lídia Roque
Sampaio,Ana
Glória,Luísa
Cravo,Marília
Torres,Joana
author_role author
country_str PT
creators_json_txt [{\"Person.name\":\"Revés,Joana Branco\"},{\"Person.name\":\"Frias-Gomes,Catarina\"},{\"Person.name\":\"Morão,Bárbara\"},{\"Person.name\":\"Nascimento,Catarina\"},{\"Person.name\":\"Palmela,Carolina\"},{\"Person.name\":\"Fidalgo,Catarina\"},{\"Person.name\":\"Ramos,Lídia Roque\"},{\"Person.name\":\"Sampaio,Ana\"},{\"Person.name\":\"Glória,Luísa\"},{\"Person.name\":\"Cravo,Marília\"},{\"Person.name\":\"Torres,Joana\"}]
datacite.creators.creator.creatorName.fl_str_mv Revés,Joana Branco
Frias-Gomes,Catarina
Morão,Bárbara
Nascimento,Catarina
Palmela,Carolina
Fidalgo,Catarina
Ramos,Lídia Roque
Sampaio,Ana
Glória,Luísa
Cravo,Marília
Torres,Joana
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
datacite.titles.title.fl_str_mv Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
dc.creator.none.fl_str_mv Revés,Joana Branco
Frias-Gomes,Catarina
Morão,Bárbara
Nascimento,Catarina
Palmela,Carolina
Fidalgo,Catarina
Ramos,Lídia Roque
Sampaio,Ana
Glória,Luísa
Cravo,Marília
Torres,Joana
dc.format.none.fl_str_mv text/html
dc.identifier.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452022000500041
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.source.none.fl_str_mv GE-Portuguese Journal of Gastroenterology v.29 n.5 2022
dc.subject.none.fl_str_mv Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
dc.title.fl_str_mv Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Abstract Introduction: Patients with inflammatory bowel disease (IBD) do not seem to be at increased risk of infection by SARS-CoV-2, but there is a concern whether immunosuppressive therapy may be associated with more severe disease. Several clinical practice recommendations have been published to help guide IBD care during the COVID-19 pandemic. Nonetheless, few studies have addressed patients’ perspectives and fears. We aimed to evaluate Portuguese IBD patients’ perspectives on the clinical management of their disease during the SARS-CoV-2 pandemic as well as the impact on their professional life. Methods: An anonymous electronic survey was created using REDCap and was distributed by the Portuguese Association of Inflammatory Bowel Disease (APDI) between May and August 2020. Patients’ perspectives on immunosuppressive therapy, disease management, interaction with gastroenterology departments, and the impact of the pandemic in their professional life were assessed. Patients’ proposals to improve medical care were also evaluated. Descriptive analysis and logistic regression were performed. Results: A total of 137 participants answered the survey (79.6% females, mean age 41.7 ± 12.1 years). Although having IBD and receiving treatment with immunosuppressors (thiopurines, steroids, or biologics) were considered promotors of anxiety, most patients (85.4%) agreed that disease remission was a priority and only a minority of patients interrupted their treatment during the pandemic. In multivariate analysis, active disease, biologic treatment, and use of corticosteroids in the last 3 months were perceived by the patients as high-risk features for increased risk of SARS-Cov-2 infection and more severe disease. Fifty-nine patients (44%) believed that their follow-up was influenced by the pandemic and only 58.8% felt that they had the opportunity to discuss their therapeutic options with their doctor. Sixty-three patients (46.0%) were working from home during the pandemic, although this decision was related to IBD and immunosuppressive therapy in only 36.5 and 39.7% of the cases, respectively. Areas where care could have been improved during the pandemic were identified by patients, namely enhancement of the communication with IBD professionals, conciliation of telemedicine with face-to-face appointments, and facilitation of the interaction between patients and employers. Conclusion: Most patients agreed that maintaining IBD remission is crucial, and only a minority of the patients stopped their treatment as per their own initiative. IBD status only had a small influence on patients’ professional activity during the COVID-19 outbreak, with most changes being related to the pandemic itself.
dirty 0
eu_rights_str_mv openAccess
format article
id scielopt_e23178bb7ffb2cd0e77a0c8d3c6aaa44
identifier.url.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452022000500041
instacron_str SciELO
institution Fundação para a Ciência e Tecnologia
instname_str Fundação para a Ciência e Tecnologia
language eng
network_acronym_str scielopt
network_name_str SciELO Portugal
oai_identifier_str oai:scielo:S2341-45452022000500041
organization_str_mv urn:organizationAcronym:scielo
person_str_mv Revés,Joana Branco
Frias-Gomes,Catarina
Morão,Bárbara
Nascimento,Catarina
Palmela,Carolina
Fidalgo,Catarina
Ramos,Lídia Roque
Sampaio,Ana
Glória,Luísa
Cravo,Marília
Torres,Joana
publishDate 2022
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
reponame_str SciELO Portugal
repository_id_str urn:repositoryAcronym:scielopt
service_str_mv urn:repositoryAcronym:scielopt
spelling Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese SurveyRevés,Joana BrancoFrias-Gomes,CatarinaMorão,BárbaraNascimento,CatarinaPalmela,CarolinaFidalgo,CatarinaRamos,Lídia RoqueSampaio,AnaGlória,LuísaCravo,MaríliaTorres,JoanaInflammatory bowel diseaseCrohn’s diseaseUlcerative colitisCOVID-19open accesshttp://purl.org/coar/access_right/c_abf2http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452022000500041URLhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452022000500041URLHasVersion2022-10-01Abstract Introduction: Patients with inflammatory bowel disease (IBD) do not seem to be at increased risk of infection by SARS-CoV-2, but there is a concern whether immunosuppressive therapy may be associated with more severe disease. Several clinical practice recommendations have been published to help guide IBD care during the COVID-19 pandemic. Nonetheless, few studies have addressed patients’ perspectives and fears. We aimed to evaluate Portuguese IBD patients’ perspectives on the clinical management of their disease during the SARS-CoV-2 pandemic as well as the impact on their professional life. Methods: An anonymous electronic survey was created using REDCap and was distributed by the Portuguese Association of Inflammatory Bowel Disease (APDI) between May and August 2020. Patients’ perspectives on immunosuppressive therapy, disease management, interaction with gastroenterology departments, and the impact of the pandemic in their professional life were assessed. Patients’ proposals to improve medical care were also evaluated. Descriptive analysis and logistic regression were performed. Results: A total of 137 participants answered the survey (79.6% females, mean age 41.7 ± 12.1 years). Although having IBD and receiving treatment with immunosuppressors (thiopurines, steroids, or biologics) were considered promotors of anxiety, most patients (85.4%) agreed that disease remission was a priority and only a minority of patients interrupted their treatment during the pandemic. In multivariate analysis, active disease, biologic treatment, and use of corticosteroids in the last 3 months were perceived by the patients as high-risk features for increased risk of SARS-Cov-2 infection and more severe disease. Fifty-nine patients (44%) believed that their follow-up was influenced by the pandemic and only 58.8% felt that they had the opportunity to discuss their therapeutic options with their doctor. Sixty-three patients (46.0%) were working from home during the pandemic, although this decision was related to IBD and immunosuppressive therapy in only 36.5 and 39.7% of the cases, respectively. Areas where care could have been improved during the pandemic were identified by patients, namely enhancement of the communication with IBD professionals, conciliation of telemedicine with face-to-face appointments, and facilitation of the interaction between patients and employers. Conclusion: Most patients agreed that maintaining IBD remission is crucial, and only a minority of the patients stopped their treatment as per their own initiative. IBD status only had a small influence on patients’ professional activity during the COVID-19 outbreak, with most changes being related to the pandemic itself.Sociedade Portuguesa de GastrenterologiaGE-Portuguese Journal of Gastroenterology v.29 n.5 2022text/htmlengjournal articlehttp://purl.org/coar/resource_type/c_6501literature
spellingShingle Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
Revés,Joana Branco
Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
status SINGLETON
subject.fl_str_mv Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
title Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
title_full Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
title_fullStr Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
title_full_unstemmed Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
title_short Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
title_sort Inflammatory Bowel Disease Patients’ Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
topic Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
topic_facet Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
COVID-19
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452022000500041
visible 1